Literature DB >> 30232664

Association of CD1 and FcγR gene polymorphisms with Guillain-Barré syndrome susceptibility: a meta-analysis.

Liang Zhang1, Lijun Liu1, Hong Li1, Lei Guo2, Qing Yu3, Jijun Teng4.   

Abstract

CD1 and immunoglobulin G Fc receptor (FcγR) genes have been proposed to be involved in the pathogenesis of Guillain-Barré syndrome (GBS). However, results of different studies are conflicting. This meta-analysis aimed to systematically examine the association between CD1 and FcγR gene polymorphisms and GBS. A comprehensive literature search through PubMed, EmBase, ScienceDirect, and Cochrane Library was performed to identify all eligible studies. The strength of association was assessed by pooled odds ratios (ORs) and corresponding 95% confidence intervals (95% CI) in allelic, dominant, recessive, homozygous and heterozygous genetic models. Four case-control studies about polymorphisms of exon 2 in CD1A and CD1E genes and GBS risk and five studies (six cohorts) about FcγR gene polymorphisms and GBS risk were included in this meta-analysis. The association between exon 2 of CD1E gene polymorphism and GBS was marginally significant in Caucasians in allelic model (OR = 1.193, 95% CI = 1.001-1.423, P = 0.049). FcγRIIA gene polymorphism was significantly associated with GBS risk in Caucasians under allelic model (OR = 1.553, 95% CI = 1.018-2.368, P = 0.041) and dominant model (OR = 1.320, 95% CI = 1.027-1.697, P = 0.030). However, no significant association was found between polymorphisms in exon 2 of CD1A, FcγRIIIA and FcγRIIIB genes and GBS susceptibility. This meta-analysis suggested that FcγRIIA gene polymorphism may contribute to GBS risk in Caucasians and revealed a certain trend toward significance in the association of exon 2 of CD1E gene with GBS in Caucasians. Further studies with larger sample size are required to validate these results.

Entities:  

Keywords:  CD1; Fcgr; Guillain–Barré syndrome; Meta-analysis; Polymorphism

Mesh:

Substances:

Year:  2018        PMID: 30232664     DOI: 10.1007/s10072-018-3563-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  34 in total

1.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

Authors:  J Wu; J C Edberg; P B Redecha; V Bansal; P M Guyre; K Coleman; J E Salmon; R P Kimberly
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.

Authors:  Nina M van Sorge; W-Ludo van der Pol; Marc D Jansen; Karin P W Geleijns; Sandra Kalmijn; Richard A C Hughes; Jeremy H Rees; Jane Pritchard; Christian A Vedeler; Kjell-Morten Myhr; Chris Shaw; Ivo N van Schaik; John H J Wokke; Pieter A van Doorn; Bart C Jacobs; Jan G J van de Winkel; Leonard H van den Berg
Journal:  J Neuroimmunol       Date:  2005-05       Impact factor: 3.478

4.  The effect of TNF-alpha, FcγR and CD1 polymorphisms on Guillain-Barré syndrome risk: evidences from a meta-analysis.

Authors:  Li-Ya Wu; You Zhou; Chao Qin; Bang-Li Hu
Journal:  J Neuroimmunol       Date:  2012-01-10       Impact factor: 3.478

5.  Fine tuning by human CD1e of lipid-specific immune responses.

Authors:  Federica Facciotti; Marco Cavallari; Catherine Angénieux; Luis F Garcia-Alles; François Signorino-Gelo; Lena Angman; Martine Gilleron; Jacques Prandi; Germain Puzo; Luigi Panza; Chengfeng Xia; Peng George Wang; Paolo Dellabona; Giulia Casorati; Steven A Porcelli; Henri de la Salle; Lucia Mori; Gennaro De Libero
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

Review 6.  Guillain-Barré syndrome.

Authors:  V Cosi; M Versino
Journal:  Neurol Sci       Date:  2006-03       Impact factor: 3.307

7.  IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome.

Authors:  W L van der Pol; L H van den Berg; R H Scheepers; J G van der Bom; P A van Doorn; R van Koningsveld; M C van den Broek; J H Wokke; J G van de Winkel
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

8.  Polymorphisms of Immunoglobulin G Fc Receptors in Pediatric Guillain-Barré Syndrome.

Authors:  Lobna A Mansour; Marian Y Girgis; Mohamed Abdulhay; Ehab I Abou ElEinein; Rabab ElHawary; Mariam Onsy F Hanna
Journal:  Neuropediatrics       Date:  2016-04-11       Impact factor: 1.947

Review 9.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

Review 10.  Mammalian CD1 and MR1 genes.

Authors:  Peter Reinink; Ildiko Van Rhijn
Journal:  Immunogenetics       Date:  2016-07-28       Impact factor: 2.846

View more
  2 in total

Review 1.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

2.  FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma.

Authors:  Yongmei Dai; Wenhan Chen; Junpeng Huang; Tongjian Cui
Journal:  Biomed Res Int       Date:  2021-07-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.